Login to Your Account



EPICADOSTAT PART OF THAT

Calithera's $480M+ tie-up with Incyte re arginase bid beats hard on combo drum

By Randy Osborne
Staff Writer

Tuesday, January 31, 2017

After one analyst earlier this month referred to Calithera Biosciences Inc.'s benefit from "pairing promiscuously" with the lead candidate in its pipeline, the company matched efforts in a different way with Incyte Corp. on an early stage prospect, and stands to collect not only $45 million up front and an $8 million equity investment but also as much as $430 million in milestone payments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription